New cocktail of drugs tested for Hard-to-Treat breast cancer – but trial halted early
NCT ID NCT03801369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tested several drug combinations for people with metastatic triple-negative breast cancer, a type that has spread and lacks common hormone targets. The drugs included olaparib (a PARP inhibitor) paired with either durvalumab (an immunotherapy), selumetinib, capivasertib, or ceralasertib alone. The goal was to see if these combinations could shrink tumors. However, the trial was terminated early after enrolling only 24 participants, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib, durvalumab, selumetinib, capivasertib, ceralasertib
What this could lead to
If successful, these drug combinations could offer new treatment options for people with metastatic triple-negative breast cancer that has stopped responding to standard therapies.
What could go wrong
This trial was terminated early with only 24 participants, so results are very limited. It is unclear if any of the combinations are effective or safe enough to move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States